Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277636 | 1.00 | KIF11 (0.55) | KIF11ACEGAAPPARGPPARA | |
| Hydrochloric Acid SCHEMBL6961108 | 0.99 | KIF11 (0.54) | KIF11ACEGAAPPARGPPARA | |
| SCHEMBL3416831 | 0.89 | ACE (0.46) | KIF11ACEGAAPPARGPPARA | |
| Hydrochloric Acid SCHEMBL3416832 | 0.87 | IDO1 (0.46) | KIF11ACEGAAPPARGPPARA | |
| Hydrochloric Acid SCHEMBL3416827 | 0.87 | IDO1 (0.46) | KIF11ACEGAAPPARGPPARA | |
| SCHEMBL530443 | 0.87 | KIF11 (0.56) | KIF11ACEGAAPPARGPPARA | |
| SCHEMBL530442 | 0.87 | KIF11 (0.56) | KIF11ACEGAAPPARGPPARA | |
| SCHEMBL918775 | 0.87 | KIF11 (0.56) | KIF11ACEGAAPPARGPPARA | |
| SCHEMBL9848804 | 0.87 | EPHX1 (0.53) | KIF11ACEGAAPPARGPPARA | |
| SCHEMBL9848809 | 0.87 | EPHX1 (0.53) | KIF11ACEGAAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889691-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| US-8569307-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2013-10-29 | — | — | US | disclosed |
| EP-2178869-B1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD (KR) | 2013-06-12 | — | — | EP | disclosed |
| US-8349885-B2 | Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect | LG LIFE SCIENCES LTD. (KR) | 2013-01-08 | — | — | US | disclosed |
| US-8309586-B2 | Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient | LG LIFE SCIENCES LTD. (KR) | 2012-11-13 | — | — | US | disclosed |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG CHEM, LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120252798-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG CHEM, LTD. (KR) | 2012-10-04 | — | — | US | disclosed |
| US-8222414-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2012-07-17 | — | — | US | disclosed |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG CHEM, LTD. (KR) | 2012-04-12 | — | — | US | disclosed |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG LIFE SCIENCES LTD. (KR) | 2010-11-18 | — | — | US | disclosed |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | LG LIFE SCIENCES LTD. (KR) | 2010-10-21 | — | — | US | disclosed |
| EP-2230238-A2 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | LG Life Sciences Ltd. (KR) | 2010-09-22 | — | — | EP | disclosed |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2010-08-19 | — | — | US | disclosed |
| EP-2178869-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG Life Sciences Ltd. (KR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009025477-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252798-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | KIF11 4468/4885ACE 2081/4885GAA 791/4885 |
| US-20140024618-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | KIF11 4468/4885ACE 2081/4885GAA 791/4885 |
| US-20120088760-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCKR, GCK, GALK1 | KIF11 2914/4885ACE 729/4885GAA 51/4885 |
| US-20120270203-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | KIF11 1608/4885ACE 2379/4885GAA 4323/4885 |
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | KIF11 1823/4885ACE 555/4885GAA 2264/4885 |
| US-20100210647-A1 | INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS | IDO1, IDO2, TNF | KIF11 4468/4885ACE 2081/4885GAA 791/4885 |
| US-20100291533-A1 | INDOLE AND INDAZOLE DERIVATIVES HAVING A CELL-, TISSUE- AND ORGAN-PRESERVING EFFECT | IDO1, IDO2, INMT | KIF11 1608/4885ACE 2379/4885GAA 4323/4885 |
| US-20100267708-A1 | GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | GCK, GCKR, HK1 | KIF11 2378/4885ACE 521/4885GAA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.